Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

ADAM R BELANGER

Allopathic & Osteopathic Physicians Internal Medicine Pulmonary Disease

NPI
1568621332
CMS profile
834753
Location
PINEHURST, NC

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2025 · Entire year

$7,370.88

109 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2025 · entire year · sorted by reported total

Nature of paymentAmountRecords
Education $5,063.38 6
Food and Beverage $2,307.50 103

By paying entity

PY2025 · entire year · sorted by reported total

Page 2 of 3; records 51–100 of 109 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

ADAM R BELANGER

NPI 1568621332 · CMS profile ID 834753

Allopathic & Osteopathic Physicians / Internal Medicine / Pulmonary Disease

PINEHURST, NC

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 2 of 3; records 51–100 of 109 matching records. This page contains 50 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1568621332?year=2025&recipient=provider&page=2#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
ADAM R BELANGER, NPI 1568621332, CMS profile ID 834753. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 3; records 51–100 of 109 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1568621332?year=2025&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
APA 7
IndustryPayments. (2026). ADAM R BELANGER, NPI 1568621332, CMS profile ID 834753. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 3; records 51–100 of 109 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1568621332?year=2025&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
Bluebook
ADAM R BELANGER, NPI 1568621332, CMS profile ID 834753, IndustryPayments, General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 3; records 51–100 of 109 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e. https://industrypayments.org/provider/npi-1568621332?year=2025&recipient=provider&page=2#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2025 · Physicians and non-physician practitioners · CMS publication 2026-06-30

109 matching records · $7,370.88 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 109 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 51–100 of 109.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Takeda Pharmaceuticals U.S.A., Inc. $21.0708/07/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1223866618 CMS
Grifols USA, LLC $31.0808/04/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1249557248 CMS
JAZZ PHARMACEUTICALS INC. $26.3308/01/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1234327396 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $16.1707/25/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1222815294 CMS
AstraZeneca Pharmaceuticals LP $14.4407/24/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1206976502 CMS
GlaxoSmithKline, LLC. $25.0007/09/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1190748690 CMS
Viatris Specialty LLC $24.6107/07/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1238482645 CMS
Grifols USA, LLC $22.5506/27/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1249557253 CMS
AstraZeneca Pharmaceuticals LP $17.8606/26/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1206231704 CMS
AstraZeneca Pharmaceuticals LP $19.1906/25/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1206136868 CMS
Verona Pharma, Inc. $21.3806/23/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1233747959 CMS
Takeda Pharmaceuticals U.S.A., Inc. $17.2906/19/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1223834909 CMS
Takeda Pharmaceuticals U.S.A., Inc. $17.2906/18/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1223834907 CMS
Regeneron Healthcare Solutions, Inc. $22.7706/16/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1212871735 CMS
Viatris Specialty LLC $10.1306/12/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1238507011 CMS
GENZYME CORPORATION $27.9806/09/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1233637690 CMS
Merck Sharp & Dohme LLC $19.9806/06/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1238113812 CMS
Merck Sharp & Dohme LLC $25.2406/05/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1238282697 CMS
Amgen Inc. $24.8705/29/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1228511109 CMS
GlaxoSmithKline, LLC. $21.9805/28/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1190513631 CMS
ANI Pharmaceuticals, Inc. $19.6105/23/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1248614634 CMS
Amgen Inc. $21.7205/22/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1228511107 CMS
Verona Pharma, Inc. $22.9105/15/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1233747967 CMS
SERVIER PHARMACEUTICALS LLC $20.2705/13/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1229090516 CMS
Viatris Specialty LLC $22.1905/07/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1238502835 CMS
GlaxoSmithKline, LLC. $22.5005/05/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1191214266 CMS
Takeda Pharmaceuticals U.S.A., Inc. $16.2305/05/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1223827172 CMS
Avadel CNS Pharmaceuticals, LLC $14.6304/30/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1208531843 CMS
Verona Pharma, Inc. $23.1504/26/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1233747971 CMS
Lilly USA, LLC $125.0004/17/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1186490903 CMS
Amgen Inc. $23.4704/15/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1228511105 CMS
GlaxoSmithKline, LLC. $15.8004/14/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1190423783 CMS
United Therapeutics Corporation $30.2004/09/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1242557068 CMS
GlaxoSmithKline, LLC. $19.6704/03/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1190503003 CMS
Viatris Specialty LLC $20.3804/03/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1238499205 CMS
Grifols USA, LLC $21.7704/02/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1249557239 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $19.9303/28/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1222815292 CMS
Verona Pharma, Inc. $18.4103/27/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1233747987 CMS
GENZYME CORPORATION $27.5503/26/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1233637674 CMS
AstraZeneca Pharmaceuticals LP $39.2803/20/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1206729284 CMS
INTUITIVE SURGICAL, INC. $2,000.0003/19/2025 Education No dispute reported Delay: No
Change: NEW
06/30/2026 1236556175 CMS
AstraZeneca Pharmaceuticals LP $26.3303/18/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1206576125 CMS
Avadel CNS Pharmaceuticals, LLC $13.4703/14/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1208531841 CMS
INTUITIVE SURGICAL, INC. $500.0003/12/2025 Education No dispute reported Delay: No
Change: NEW
06/30/2026 1236556177 CMS
Amgen Inc. $20.3803/06/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1228511103 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $10.1202/27/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1222815290 CMS
Regeneron Healthcare Solutions, Inc. $23.3002/27/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1212871733 CMS
Viatris Specialty LLC $31.6602/26/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1238511389 CMS
INTUITIVE SURGICAL, INC. $2,000.0002/21/2025 Education No dispute reported Delay: No
Change: NEW
06/30/2026 1236556173 CMS
Merck Sharp & Dohme LLC $30.9802/21/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1238113814 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $4,693.48 8
PY2020 $4,520.00 17
PY2021 $19,016.88 58
PY2022 $18,328.62 59
PY2023 $24,610.85 126
PY2024 $17,465.54 93
PY2025 $7,370.88 109

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $23,306.16 25
PY2024 Principal investigator $47,680.50 5
PY2023 Principal investigator $143,000.25 3
PY2022 Principal investigator $27,606.25 1

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

25 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Boehringer Ingelheim International GmbH $7.08 12/01/2025 Non-covered Recipient Entity
Pinehurst Medical Clinic-East
A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) No dispute reported 06/30/2026 1220630773
Principal investigator 1 Boehringer Ingelheim International GmbH $11.29 12/01/2025 Non-covered Recipient Entity
Pinehurst Medical Clinic-East
A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) No dispute reported 06/30/2026 1220630775
Principal investigator 1 Boehringer Ingelheim International GmbH $94.42 12/01/2025 Non-covered Recipient Entity
Pinehurst Medical Clinic-East
A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) No dispute reported 06/30/2026 1220630777
Principal investigator 1 Boehringer Ingelheim International GmbH $263.04 12/01/2025 Non-covered Recipient Entity
Pinehurst Medical Clinic-East
A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) No dispute reported 06/30/2026 1220630779
Principal investigator 1 Boehringer Ingelheim International GmbH $799.00 11/01/2025 Non-covered Recipient Entity
Pinehurst Medical Clinic-East
A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) No dispute reported 06/30/2026 1220630763
Principal investigator 1 Boehringer Ingelheim International GmbH $7.08 11/01/2025 Non-covered Recipient Entity
Pinehurst Medical Clinic-East
A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) No dispute reported 06/30/2026 1220630765
Principal investigator 1 Boehringer Ingelheim International GmbH $11.29 11/01/2025 Non-covered Recipient Entity
Pinehurst Medical Clinic-East
A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) No dispute reported 06/30/2026 1220630767
Principal investigator 1 Boehringer Ingelheim International GmbH $94.42 11/01/2025 Non-covered Recipient Entity
Pinehurst Medical Clinic-East
A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) No dispute reported 06/30/2026 1220630769
Principal investigator 1 Boehringer Ingelheim International GmbH $263.04 11/01/2025 Non-covered Recipient Entity
Pinehurst Medical Clinic-East
A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) No dispute reported 06/30/2026 1220630771
Principal investigator 1 Boehringer Ingelheim International GmbH $174.90 10/27/2025 Non-covered Recipient Entity
Pinehurst Medical Clinic-East
A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) No dispute reported 06/30/2026 1220630781
Principal investigator 1 Boehringer Ingelheim International GmbH $19.98 10/27/2025 Non-covered Recipient Entity
Pinehurst Medical Clinic-East
A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) No dispute reported 06/30/2026 1220630783
Principal investigator 1 Boehringer Ingelheim International GmbH $401.50 10/27/2025 Non-covered Recipient Entity
Pinehurst Medical Clinic-East
A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) No dispute reported 06/30/2026 1220630785
Principal investigator 1 Boehringer Ingelheim International GmbH $9.28 10/27/2025 Non-covered Recipient Entity
Pinehurst Medical Clinic-East
A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) No dispute reported 06/30/2026 1220630787
Principal investigator 1 Boehringer Ingelheim International GmbH $65.55 10/27/2025 Non-covered Recipient Entity
Pinehurst Medical Clinic-East
A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) No dispute reported 06/30/2026 1220630789
Principal investigator 1 Boehringer Ingelheim International GmbH $30.00 10/27/2025 Non-covered Recipient Entity
Pinehurst Medical Clinic-East
A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) No dispute reported 06/30/2026 1220630791
Principal investigator 1 Boehringer Ingelheim International GmbH $263.04 10/01/2025 Non-covered Recipient Entity
Pinehurst Medical Clinic-East
A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) No dispute reported 06/30/2026 1220630753
Principal investigator 1 Boehringer Ingelheim International GmbH $191.71 10/01/2025 Non-covered Recipient Entity
Pinehurst Medical Clinic-East
A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) No dispute reported 06/30/2026 1220630755
Principal investigator 1 Boehringer Ingelheim International GmbH $94.42 10/01/2025 Non-covered Recipient Entity
Pinehurst Medical Clinic-East
A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) No dispute reported 06/30/2026 1220630757
Principal investigator 1 Boehringer Ingelheim International GmbH $11.29 10/01/2025 Non-covered Recipient Entity
Pinehurst Medical Clinic-East
A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) No dispute reported 06/30/2026 1220630759
Principal investigator 1 Boehringer Ingelheim International GmbH $7.08 10/01/2025 Non-covered Recipient Entity
Pinehurst Medical Clinic-East
A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) No dispute reported 06/30/2026 1220630761
Principal investigator 1 Galvanize Therapeutics, Inc $1,712.50 09/15/2025 Non-covered Recipient Entity
PINEHURST MEDICAL CLINIC
CS006 RHEOX PIVOTAL No dispute reported 06/30/2026 1238409123
Principal investigator 1 Galvanize Therapeutics, Inc $3,425.00 07/09/2025 Non-covered Recipient Entity
PINEHURST MEDICAL CLINIC
CS006 RHEOX PIVOTAL No dispute reported 06/30/2026 1238409093
Principal investigator 1 Galvanize Therapeutics, Inc $4,075.00 03/14/2025 Non-covered Recipient Entity
PINEHURST MEDICAL CLINIC
CS006 RHEOX PIVOTAL No dispute reported 06/30/2026 1238409045
Principal investigator 1 Galvanize Therapeutics, Inc $5,993.00 01/17/2025 Non-covered Recipient Entity
FIRST HEALTH
CS006 RHEOX PIVOTAL No dispute reported 06/30/2026 1238408997
Principal investigator 1 Galvanize Therapeutics, Inc $5,281.25 01/17/2025 Non-covered Recipient Entity
PINEHURST MEDICAL CLINIC
CS006 RHEOX PIVOTAL No dispute reported 06/30/2026 1238409003